Enterprise Value

443.3M

Cash

72.45M

Avg Qtr Burn

-11.76M

Short % of Float

6.89%

Insider Ownership

3.87%

Institutional Own.

44.82%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Recorlev® (levoketoconazole) Details
Rare diseases, Cushing’s syndrome

Approved

Quarterly sales

Approved

Quarterly sales

Phase 2

Data readout

Failed

Discontinued

Gvoke RTU Micro™ Details
Hypoglycemia, Type 1 diabetes, Type 2 diabetes

Failed

Discontinued

Pramlintide-Insulin Details
Type 1 diabetes, Diabetes, Type 2 diabetes

Failed

Discontinued